Aldevron has added six new employees in its Fargo location, including Steve Chalfant, Pragya Dahal, Maureen Krogstad, Audra Puppe, David Fellen and Michael Schmidt.
Aldevron, Sanford Health, North Dakota State University highlight advances in rare disease treatment
Area organizations Aldevron, Sanford Health, and North Dakota State University (NDSU) have joined forces to bring together a special event titled, "From the Valley to the Mountain: The RARE Impact of the Red River Valley," on Wednesday, April 11 from 5:30-8 p.m. at Aldevron corporate headquarters, 4837 Amber Valley Parkway, Fargo N.D. The evening will start with refreshments, a Meet and Greet, and a silent auction, followed by leaders in science and medicine from the Red River Valley sharing their contributions toward advancing gene therapy and rare disease research efforts around the world.
Aldevron has selected AES Clean Technology, a leader in the design, manufacturing, and construction of modular cleanroom systems, to design modular cleanrooms for Aldevron’s $30 million, 70,000 square-foot manufacturing facility in Fargo, N.D. Cleanroom construction is underway with target completion date of early summer.
New plasmid to reduce cost and timeline for gene therapy manufacturing
Aldevron, the world’s leading contract plasmid manufacturing organization, has announced the immediate availability of an off-the-shelf version of pXX6-80, a common adeno-associated virus (AAV) helper plasmid. The plasmid is designed to reduce the cost of AAV manufacturing and subsequent gene therapy applications, while helping Aldevron’s clients meet regulatory requirements.
Aldevron is a sponsor for the Rare Disease Day program, "Gene Therapy for Rare Diseases: Promise and Challenges", presented by the University of Minnesota Center for Orphan Drug Research and Stem Cell Institute on February 23, 2018. Dr. Jakub Tolar, Dean, Medical School, University of Minnesota, will moderate the event, which will include presentations by University of Minnesota faculty and a representative from Abeona Therapeutics.
Aldevron and Integrated DNA Technologies, Inc. (IDT), a supplier of custom nucleic acid and genome editing products, have announced a license agreement whereby Aldevron will manufacture and distribute a S. pyogenes Cas9 variant—known as SpyFiTM Cas9 Nuclease—which is patented by IDT. The product will be manufactured for research, clinical, and commercial use.